Immunomodulators in warts: Unexplored or ineffective?

Area of Science:

• Dermatology
• Immunology
• Virology

Background:

• Cutaneous warts are frequently recurrent and resistant to conventional destructive therapies.
• Resistance may indicate a localized or systemic cell-mediated immune deficiency to human papillomavirus (HPV).
• Existing treatments like cryotherapy and laser removal can cause scarring, while topical agents risk site reactions and recurrence.

Purpose of the Study:

• To review immunomodulatory agents used in treating cutaneous warts.
• To evaluate the efficacy and safety of different immunotherapy approaches.
• To discuss the potential of immunotherapy for achieving complete wart resolution and preventing recurrence.

Main Methods:

• Literature review of studies on immunomodulators for wart treatment.
• Analysis of systemic, intralesional, intradermal, and topical administration routes.
• Examination of established agents (e.g., cimetidine, interferons) and emerging therapies (e.g., Echinacea, green tea catechins, HPV vaccine).

Main Results:

• Immunotherapy aims for wart resolution without scarring and enhanced host response.
• Established agents like cimetidine and interferons have shown varying degrees of efficacy.
• Newer agents require further large-scale, randomized, placebo-controlled trials to confirm effectiveness.
• Some agents, like levamisole, are effective only in combination therapy.

Conclusions:

• Immunotherapy presents a viable alternative to destructive treatments for recalcitrant warts.
• Further research, particularly robust clinical trials, is essential to establish the efficacy of novel immunomodulators.
• Harnessing the immune system offers a pathway to improved wart management with reduced side effects and recurrence rates.